MedTrace Logo

Reflux Esophagitis Phase III Study (Initial Treatment)

NCT00633932 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 602

Last updated 2010-12-20

Study results available
· View outcomes & findings →

Summary

This study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily for 8 weeks on healing of Reflux Esophagitis in patients with reflux esophagitis in comparison with omeprazole 20 mg once daily by assessment of presence/absence of Reflux Esophagitis at Week 8 according to the Los Angeles classification .

Conditions

  • Reflux Esophagitis

Interventions

DRUG

Esomeprazole

20mg once daily

DRUG

Esomeprazole

40 mg once daily

DRUG

Omeprazole

20mg once daily

Sponsors & Collaborators

Principal Investigators

  • Maotsugu Oyama, MD, PhD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Completion
2008-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00633932 on ClinicalTrials.gov